172 related articles for article (PubMed ID: 25296077)
41. Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials.
Wang Y; Yang H; Wei JF; Meng L
Curr Med Res Opin; 2012 Dec; 28(12):1911-9. PubMed ID: 23145857
[TBL] [Abstract][Full Text] [Related]
42. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
Wagstaff AJ; Ibbotson T; Goa KL
Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
[TBL] [Abstract][Full Text] [Related]
43. Capecitabine-induced inflammation of actinic keratosis: case report and literature review.
Stanciu M; Aubut N; Gagné E; Thibeault MM
J Cutan Med Surg; 2012; 16(5):298-9. PubMed ID: 22971302
[No Abstract] [Full Text] [Related]
44. Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
Brearley SG; Craven O; Saunders M; Swindell R; Molassiotis A
Eur J Cancer Care (Engl); 2010 Jul; 19(4):425-33. PubMed ID: 19708942
[TBL] [Abstract][Full Text] [Related]
45. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
46. Current combination chemotherapy regimens for metastatic breast cancer.
Schwartz J
Am J Health Syst Pharm; 2009 Dec; 66(23 Suppl 6):S3-8. PubMed ID: 19923317
[TBL] [Abstract][Full Text] [Related]
47. Capecitabine dosing is not yet optimized for breast cancer.
Hudis C; Traina T; Norton L
Ann Oncol; 2010 Nov; 21(11):2291; author reply 2291-2. PubMed ID: 20501505
[No Abstract] [Full Text] [Related]
48. [Capecitabine: an oral chemotherapeutic agent against metastatic breast and colorectal cancer].
Calzas Rodríguez J; de la Nogal Fernández B; Arrieta Garmendia JM; Lastra Aras E; García Castaño A; Barrio Gil-Fournier A; García Girón C
Farm Hosp; 2003; 27(3):171-8. PubMed ID: 12835819
[TBL] [Abstract][Full Text] [Related]
49. Response to low-dose oral capecitabine monotherapy in an elderly frail patient with metastatic breast carcinoma and impaired renal function: documentation by fluorodeoxyglucose positron emission tomography.
Basu S; Baghel NS
Jpn J Radiol; 2011 May; 29(4):291-2. PubMed ID: 21607846
[No Abstract] [Full Text] [Related]
50. Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer.
Yu CS; Kim TW; Kim JH; Choi WS; Kim HC; Chang HM; Ryu MH; Jang SJ; Ahn SD; Lee SW; Shin SS; Choi EK; Kim JC
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1020-6. PubMed ID: 17197127
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer.
Di Seri M; De Sanctis R; Quadrini S; Adua D; Stumbo L; Del Signore E; Gori B; Grassi P; Basile ML; Longo F
J Chemother; 2011 Apr; 23(2):110-3. PubMed ID: 21571629
[TBL] [Abstract][Full Text] [Related]
52. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
53. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
[TBL] [Abstract][Full Text] [Related]
54. Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Seminara P; Losanno T; Emiliani A; Manna G
Cardiology; 2010; 116(1):42-4. PubMed ID: 20431291
[TBL] [Abstract][Full Text] [Related]
55. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
56. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Traina TA; Theodoulou M; Feigin K; Patil S; Tan KL; Edwards C; Dugan U; Norton L; Hudis C
J Clin Oncol; 2008 Apr; 26(11):1797-802. PubMed ID: 18398145
[TBL] [Abstract][Full Text] [Related]
57. Capecitabine-related cardiotoxicity: recognition and management.
Saif MW; Tomita M; Ledbetter L; Diasio RB
J Support Oncol; 2008 Jan; 6(1):41-8. PubMed ID: 18257400
[No Abstract] [Full Text] [Related]
58. Evolution of capecitabine dosing in breast cancer.
Naughton M
Clin Breast Cancer; 2010 Apr; 10(2):130-5. PubMed ID: 20299321
[TBL] [Abstract][Full Text] [Related]
59. Capecitabine: effective oral fluoropyrimidine chemotherapy.
McKendrick J; Coutsouvelis J
Expert Opin Pharmacother; 2005 Jun; 6(7):1231-9. PubMed ID: 15957975
[TBL] [Abstract][Full Text] [Related]
60. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]